Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes

US5831016A · kind A · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Rong Wang · Mianyang, CN
• Steven A. Rosenberg · Potomac, US

Key dates

• Filing date: Oct 4, 1996
• Grant date: Nov 3, 1998
• Expiry date: Oct 4, 2016

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S530/828
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The infusion of TIL586 along with interleukin-2 (IL-2) into the autologous patient with metastatic melanoma resulted in the objective regression of tumor. A gene encoding a tumor antigen recognized by TIL586 was previously isolated and shown to encode gp75 or TRP-1. The present invention relates to the identification of a second tumor antigen recognized by a HLA-A31 restricted CTL clone derived from the TIL586 cell line. This antigen derived from the TRP-2 protein tumor antigen and peptides thereof are capable of sensitizing target cells for lysis by a CTL clone at 1 nM peptide concentration. Modified peptides were also recognized by the CTL clone.